rs11543198 - CLK3
Magnitude 2.8 · 1 study on file
Reported associations
-
Genome-wide association study identified SNP on 15q24 associated with bladder cancer risk in Japanese population. - Human molecular genetics (2015) · Matsuda K, Takahashi A, Middlebrooks CD, Obara W, Nasu Y, Inoue K, Tamura K, Yamasaki I, Naya Y, Tanikawa C, Cui R, Figueroa JD, Silverman DT, Rothman N, Namiki M, Tomita Y, Nishiyama H, Kohri K, Deguchi T, Nakagawa M, Yokoyama M, Miki T, Kumon H, Fujioka T, Prokunina-Olsson L, Kubo M, Nakamura Y, Shuin T · PubMed 25281661
Through genome-wide association analysis and an independent replication study using a total of 1131 bladder cancer cases and 12 558 non-cancer controls of Japanese populations, we identified a susceptibility locus on chromosome 15q24. SNP rs11543198 was associated with bladder cancer risk with odds ratio (OR) of 1.41 and P-value of 4.03 × 10(-9). Subgroup analysis revealed rs11543198 to have a stronger effect in male smokers with OR of 1.66. SNP rs8041357, which is in complete linkage disequilibrium (r(2) = 1) with rs11543198, was also associated with bladder cancer risk in Europeans (P = 0.045 for an additive and P = 0.025 for a recessive model), despite much lower minor allele frequency in Europeans (3.7%) compared with the Japanese (22.2%). Imputational analysis in this region suggeste
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Lifestyle
-
smoking High
rs11543198 G-allele carriers metabolize tobacco carcinogens through CYP1A2; carriers show 1.41-fold baseline bladder cancer risk and 1.66-fold risk when smoking
complete avoidance of cigarettes and tobacco products; if current smoker, consult healthcare provider on cessation plan
Screening
-
bladder cancer screening Moderate
rs11543198 G-allele carriers have 1.41-fold elevated bladder cancer risk (p=4.03e-9) with replication across populations; trait is clinically actionable
discuss with urologist or oncologist regarding age-appropriate screening and modality